| | 
| | |  |  | Webcast
Idera Pharmaceuticals, Inc. at Rodman & Renshaw Global Investment Conference (Live)
09/15/10 at 10:50 a.m. ET |
| Webcast
Idera Pharmaceuticals, Inc. at UBS Global Life Sciences Conference (Live)
09/20/10 at 7:30 a.m. ET |
|
|
|
| Date | Title | | | 12/21/09 | Idera Pharmaceuticals Announces Positive Interim Data from Phase 1
Clinical Trial of IMO-2125 in Chronic Hepatitis C Patients| CAMBRIDGE, Mass., Dec 21, 2009 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced positive
interim results from a Phase 1 clinical trial of IMO-2125 in patients
with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist
of Toll-like Receptor 9 that Idera designed to treat HCV by inducing
endogenous interferon-alpha and other Th1-type cytokines and chemokines.
In this four-week trial, IMO-2125 was well tolerated and induced
... |
|  | | 12/04/09 | Idera Pharmaceuticals Appoints Rahul Jasuja, Ph.D., Vice President of Corporate Development| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 4, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), announced today the
appointment of Rahul Jasuja, Ph.D., as Vice President of Corporate
Development. Dr. Jasuja previously served as Managing Director, Life
Sciences at MDB Capital Group, a life sciences and technology ... |
| | | 11/25/09 | Idera Pharmaceuticals and Merck & Co., Inc. Extend Research Collaboration for Agonists of Toll-like Receptors as Vaccine Adjuvants| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Merck &
Co., Inc., through an affiliate, has extended its research collaboration
with Idera for a fourth year. In December 2006, the companies entered
into an exclusive license and research collaboration agreement to
research, develop, and commercialize vaccine products containing the
Company’s investigational agonist compounds... |
| | | 11/25/09 | Idera Pharmaceuticals Announces Termination of Asthma and Allergy Research Collaboration Agreement|
- Idera to Regain Full Rights to IMO-2134 (formerly QAX935) -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 25, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that
Novartis will terminate its research collaboration agreement with the
Company, effective as of February 21, 2010.
“We appreciate the commitment Novartis scientists provided throughout
our four-plus years of collaboration, during which Novartis select... |
| | | 11/05/09 | Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 5, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial
results for the third quarter and nine months ended September 30, 2009.
“We have continued development of our pipeline of drug candidates
targeted to Toll-like receptors for potential applications in chronic
hepatitis C virus infection and autoimmune diseases, and to support our
partnered programs in oncology, respiratory dise... |
| | | 11/03/09 | Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009|
- IMO-2125 Induces Endogenous Interferons and Other Antiviral Proteins
-
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical
data on the mechanism by which IMO-2125 was shown to induce immune
activation through Toll-like Receptor 9 (TLR9). Two presentations are
being made today at the 60th Annual Meeting of the American
Association for the Study of Liver Diseases being... |
| | | 10/26/09 | Idera Pharmaceuticals Announces Issuance of Patents Covering its Novel Toll-like Receptor-Targeted Compounds and Their Use| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance
of patents covering its novel Toll-like Receptor (TLR) - targeted
compounds. The Company’s TLR-targeted compounds are based on synthetic
DNA and RNA, which it refers to as immune modulatory oligonucleotides,
or IMO®. Idera’s intellectual property portfolio contains
over 500 patents and patent applications worldwide, which include... |
| | | 10/19/09 | Idera Pharmaceuticals Presents Preclinical Data at ACR/ARHP 2009 Annual Meeting on IMO-3100, a Toll-Like Receptor Antagonist, in Combination with Enbrel(R) in Arthritis Model| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 19, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
presentation of preclinical data from studies of IMO-3100 in combination
with Enbrel (etanercept) in a mouse model of arthritis. IMO-3100, an
antagonist of Toll-like Receptor (TLR) 7 and TLR9, is a lead drug
candidate that Idera is developing for potential applications in
autoimmune diseases. Enbrel is an inhibitor of TNF-alpha currently ... |
| | | 10/16/09 | Idera Pharmaceuticals to Present at 8th Annual BIO Investor Forum| CAMBRIDGE, Mass., Oct 16, 2009 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its drug discovery and development programs and provide
a general corporate overview at the 8th Annual BIO Investor
Forum on Thursday, October 29, at 11:30 a.m. PT (2:30 p.m. ET) at the
... |
| | | 10/07/09 | Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 7, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that patient
treatment has been initiated in a phase 1 clinical trial evaluating
IMO-2125 in combination with ribavirin in treatment-naive patients with
chronic hepatitis C virus (HCV) infection. IMO-2125 is a novel agonist
of Toll-like Receptor (TLR) 9.
“We expect that the IMO-2125 trial with ribavirin in treatment-naïve HCV
... |
| | | 10/01/09 | Idera Pharmaceuticals to Present at 11th Annual Massachusetts Biotechnology Investors Forum| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its drug discovery and development programs and provide
a general corporate overview at the 11th Annual Massachusetts
Biotechnology Investors Forum on Tuesday, October 6, 2009, at 3... |
| | | 09/25/09 | Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 25, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the
presentation of final data from a clinical trial evaluating IMO-2055, an
agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with
Renal Cell Carcinoma (RCC). The data are being presented during the
Eighth International Kidney Cancer Symposium being held in Chicago,
September 25-26, 2009.
In this phase 2 open-... |
| | | 09/23/09 | Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva(R) and Avastin(R) in Non-Small Cell Lung Cancer| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 23, 2009--
Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a
phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of
Toll-like Receptor (TLR) 9, in combination with Tarceva® and
Avastin® in patients with non-small cell lung cancer (NSCLC).
The data were presented during the joint 15th Congress of the European
CanCer Organisation (ECCO) and 34th Congress of the European Soci... |
| | | 09/15/09 | Idera Pharmaceuticals to Present at UBS Global Life Sciences Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 15, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its TLR-targeted drug discovery and development programs
and provide a general corporate overview at the UBS Global Life Sciences
Conference on Monday, September 21, 2009, at 10:30... |
| | | 09/03/09 | Idera Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 3, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its TLR-targeted drug discovery and development programs
and provide a general corporate overview at the Rodman & Renshaw Annual
Global Investment Conference on Thursday, Septem... |
| | | 08/04/09 | Idera Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides Pipeline Update| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 4, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial
results for the second quarter and six months ended June 30, 2009.
“Over the next 12-18 months, we expect that results from ongoing
clinical trials in our hepatitis C program and our partnered oncology
and respiratory disease programs will enable decisions to be made for
subsequent steps in the development for these indication... |
| | | 07/31/09 | Idera Pharmaceuticals to Present at Upcoming Investor Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 31, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will discuss its TLR-targeted drug discovery and development programs
and provide a general corporate overview at the following conferences:
The BMO Capital Markets 9th Annual... |
| | | 06/16/09 | Idera Pharmaceuticals Provides Update on Drug Candidate Pipeline Targeted to Toll-like Receptors| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA - News) today provided an update on its drug candidate pipeline targeted to Toll-like Receptors (TLRs) during its 2009 Annual Meeting of Stockholders.
“We have three drug candidates in clinical evaluation for multiple indications, two of which are being advanced by our partners. We expect to file an IND application for a fourth drug candidate by the end of 2009,” said Sudhir Agrawal, D. Phil., President, Chie... |
| | | 06/15/09 | Idera Pharmaceuticals Announces Presentations of Preclinical Data on Modulation of Toll-like Receptors 3, 7, and 9 through Antisense| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that Idera
scientists presented data from preclinical studies on modulation of
Toll-Like Receptors (TLRs) 3, 7, and 9 through antisense in three
presentations at the Federation of Clinical Immunology Societies (FOCIS)
2009 Annual Meeting held in San Francisco, CA, June 11-14.
“We have combined our pioneering work in antisense technolo... |
| | | 06/01/09 | Idera Pharmaceuticals to Present at Noble Financial Capital Market's Fifth Annual Equity Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will present a corporate overview at the Noble Financial Capital
Market’s Fifth Annual Equity Conference on Monday, June 8, at 10:25 a.m.
(EDT) at The Hard Rock Hotel in Hollywood, FL.
... |
| | | 05/15/09 | Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Panel at BIO 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 15, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced its
participation in two sessions at the 2009 BIO International Convention
taking place May 18-21, 2009 at the Georgia World Congress Center in
Atlanta, GA.
Sudhir Agrawal, D. Phil., P... |
| | | 05/11/09 | Idera Pharmaceuticals Announces Presentation of Preclinical Data on IMO-3100, a Lead TLR Antagonist Drug Candidate for Autoimmune Diseases, during American Association of Immunologists Annual Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 11, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
presentation of data from a preclinical study of antagonist effects of
IMO-3100 on gene expression profiles induced by ligands of specific
Toll-like Receptors (TLRs). The presentation entitled “IMO-3100, an
Antagonist of Toll-like Receptors 7 and 9, Modulates Gene Expression and
Regulatory Networks Induced by Ligands” was given by Idera s... |
| | | 05/06/09 | Idera Pharmaceuticals Reports First Quarter 2009 Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 6, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial
results for the first quarter ended March 31, 2009.
“We currently have three novel agonists targeted to Toll-like Receptors
in clinical development for different indications, two of which are
being advanced and funded by our collaborators,” said Sudhir Agrawal,
D.Phil., President, Chief Executive Officer and Chie... |
| | | 04/23/09 | Idera Pharmaceuticals Announces Issuance of Patents Claiming Novel Toll-like Receptor-Targeted Immune Modulatory Oligonucleotides and Their Use| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 23, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance
of patents covering its novel immune modulatory oligonucleotides (IMO),
chemical modifications of IMOs, compositions containing IMOs with other
therapeutic agents, and the use of IMOs to therapeutically treat a broad
range of diseases.
The issued patents include:
US 7,517,862, entitled “Modulation... |
| | | 04/15/09 | Idera Pharmaceuticals to Present Preclinical Data on its Agonists of Toll-Like Receptors at AACR 2009 Annual Meeting| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 15, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that data
from evaluations of a dual Toll-like Receptor 7 (TLR7) and TLR8 agonist
and a TLR9 agonist in preclinical models of cancer will be presented at
the 2009 Annual Meeting of the American Association for Cancer Research
(AACR) being held in Denver, CO, April 18-22, 2009. The presentations
are as follows:
Wednesday, April... |
| | | 03/11/09 | Idera Pharmaceuticals Reports 2008 Fourth Quarter and Full Year Financial Results| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 11, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported financial
results for the fourth quarter and full year ended December 31, 2008.
“Together with our collaborators, we currently have three novel
Toll-like Receptor-targeted drug candidates undergoing clinical
evaluation in multiple indications, and we expect to submit an IND for a
fourth compound, IMO-3100, by the end of 2009,” said Sud... |
| | | 03/10/09 | Idera Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 10, 2009--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will present a corporate overview at the Cowen and Company 29th
Annual Health Care Conference on Wednesday, March 18, at 10:15 a.m. (ET)
at the Boston Marriott Copley Place in Boston, MA.
... |
| | | 03/04/09 | Idera Pharmaceuticals Scientists Co-Author Paper on Preclinical Data of Investigational Cancer Vaccine| CAMBRIDGE, Mass., Mar 04, 2009 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced the
publication of a paper entitled "Treatment of Mammary Carcinomas in
HER-2 Transgenic Mice through Combination of Genetic Vaccine and an
Agonist of Toll-like Receptor 9" in Clinical Cancer Research
... |
| | | 02/02/09 | Idera Pharmaceuticals Announces Achievement of Clinical Milestone Under its Collaboration with Merck KGaA for Cancer Treatment| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has
achieved a milestone under its worldwide licensing and collaboration
agreement with Merck KGaA upon the dosing of the first patient in a
clinical study of IMO-2055 in combination with Erbitux® and Camptosar®
in patients with colorectal cancer. Under the terms of the agreement,
the Company is entitled to receive a payment of €3.0 million ($3.8
... |
| | | 01/30/09 | Idera Pharmaceuticals to Present at Annual BIO CEO & Investor Conference 2009| CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company
engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-like Receptors (TLR), today announced that
it will present a corporate overview at the 11th Annual BIO CEO &
Investor Conference on Monday, February 9 at 10:30 a.m. (ET) at the
Waldorf=Astoria hotel in New York City.
The presentation will ... |
| | | 01/05/09 | Idera Pharmaceuticals Announces Publication of Studies on Chemistry of Novel Antagonists for Toll-like Receptors 7 and 9| - Antagonist Compounds Have Potential Application in Autoimmune and Inflammatory Diseases -
CAMBRIDGE, Mass., Jan 05, 2009 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the
publication of studies on the chemistry of novel compounds that have
been shown to act as antagonists for Toll-like Receptors (TLR) 7 and 9.
These antagonist candidates have potential application in autoimmune and
inflammatory diseases. The paper entitled
... |
| |
|
|
| |
